Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy.
Current progress in nanomedicine has exploited the possibility of designing tumor-targeted nanocarriers being able to deliver radionuclide payloads in a site or molecular selective manner to improve the efficacy and safety of cancer imaging and therapy. Radionuclides of auger electron-, alpha-, beta-, and gamma-radiation emitters have been surface-bioconjugated or after-loaded in nanoparticles to improve the efficacy and reduce the toxicity of cancer imaging and therapy in preclinical and clinical studies. This article provides a brief overview of current status of applications, advantages, problems, up-to-date research and development, and future prospects of nanotargeted radionuclides in cancer nuclear imaging and radiotherapy. Passive and active nanotargeting delivery of radionuclides with illustrating examples for tumor imaging and therapy are reviewed and summarized. Research on combing different modes of selective delivery of radionuclides through nanocarriers targeted delivery for tumor imaging and therapy offers the new possibility of large increases in cancer diagnostic efficacy and therapeutic index. However, further efforts and challenges in preclinical and clinical efficacy and toxicity studies are required to translate those advanced technologies to the clinical applications for cancer patients.
Ting
Gann
G
Center of Nanomedicine and National Institute of Cancer Research, National Health Research Institutes, 35053 Miaoli, Taiwan.
Chang
Chih-Hsien
CH
Wang
Hsin-Ell
HE
Lee
Te-Wei
TW
D000818:Animals; D003952:Diagnostic Imaging / Q000379:methods*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D050997:Nanomedicine / Q000379:methods*; D009369:Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D011878:Radiotherapy / Q000379:methods*
D011868:Radioisotopes
Radiother Oncol. 2003 Feb;66(2):107-17
12648782
Bioconjug Chem. 2008 Jul;19(7):1496-504
18578485
Nat Rev Cancer. 2005 Mar;5(3):161-71
15738981
Br J Cancer. 2008 Aug 5;99(3):392-7
18648371
J Nucl Med. 2006 Jun;47(6):1023-31
16741313
J Liposome Res. 2007;17(3-4):121-37
18027233
Clin Pharmacokinet. 2003;42(5):419-36
12739982
Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S74-82
16979445
Q J Nucl Med Mol Imaging. 2008 Sep;52(3):267-77
18475250
Curr Pharm Des. 2006;12(36):4729-49
17168775
J Nucl Med. 2001 Mar;42(3):499-504
11337529
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1215-27
15001266
Nat Rev Immunol. 2006 May;6(5):343-57
16622479
J Med Chem. 2007 Dec 27;50(26):6454-7
18052025
Clin Cancer Res. 2001 Feb;7(2):243-54
11234875
Bioconjug Chem. 2009 Apr;20(4):648-55
19368341
Nanomedicine (Lond). 2007 Oct;2(5):711-24
17976032
FEBS Lett. 1990 Jul 30;268(1):235-7
2384160
J Nucl Med. 2007 Jun;48(6):1000-7
17504875
Clin Oncol (R Coll Radiol). 2000;12(1):2-15
10749014
Bioconjug Chem. 2008 Dec;19(12):2577-84
18991368
Clin Oncol (R Coll Radiol). 2000;12(1):16-24
10749015
Clin Cancer Res. 2008 Feb 1;14(3):731-41
18245533
Int J Cancer. 2007 Jun 15;120(12):2527-37
17390371
Phys Med Biol. 2003 May 21;48(10):1305-20
12812448
J Control Release. 2004 Nov 5;100(1):135-44
15491817
Expert Opin Med Diagn. 2008 Jul;2(7):853-73
23495822
Nucl Med Biol. 2008 Jul;35(5):623-34
18589307
Nat Nanotechnol. 2008 Mar;3(3):151-7
18654487
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jan-Feb;1(1):69-83
20049780
Bioconjug Chem. 2008 Jun;19(6):1274-82
18505278
Nanomedicine. 2008 Dec;4(4):273-82
18640076
Clin Cancer Res. 2008 Jun 15;14(12):3975-83
18559620
Br J Clin Pharmacol. 2008 Jul;66(1):6-19
18503606
Nat Rev Drug Discov. 2007 May;6(5):349-56
17431406
J Nucl Med. 2003 Dec;44(12):1945-61
14660721
Nat Nanotechnol. 2007 Aug;2(8):469-78
18654343
Adv Drug Deliv Rev. 2008 May 22;60(8):929-38
18313790
Nat Rev Drug Discov. 2008 Sep;7(9):771-82
18758474
Science. 2006 Feb 3;311(5761):622-7
16456071
Mol Pharm. 2009 May-Jun;6(3):928-39
19278222
J Nucl Med. 2009 Apr;50(4):582-90
19289423
Nat Nanotechnol. 2008 May;3(5):242-4
18654511
J Nucl Med. 1986 Aug;27(8):1300-7
3734903
Eur J Nucl Med Mol Imaging. 2009 May;36(5):869-74
19288097
Bioconjug Chem. 2008 Dec;19(12):2471-9
19035793
Int J Nanomedicine. 2008;3(1):21-9
18488413
Oncogene. 2007 May 28;26(25):3614-28
17530015
Clin Cancer Res. 2000 Dec;6(12):4939-49
11156255
Adv Drug Deliv Rev. 2008 Aug 17;60(11):1226-40
18495291
J Nucl Med. 2005 Sep;46(9):1552-60
16157540
Br J Cancer. 2008 Sep 16;99(6):900-10
19238631
Biomed Pharmacother. 2006 Jan;60(1):43-50
16260113
Nucl Med Biol. 2008 Nov;35(8):883-93
19026950
J Pharmacol Exp Ther. 2000 Oct;295(1):309-13
10991995
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
1763060
Anticancer Res. 2000 Sep-Oct;20(5A):3339-45
11062762
J Nucl Med. 2000 Mar;41(3):429-38
10716315
Nucl Med Biol. 2007 Feb;34(2):165-71
17307124
Adv Drug Deliv Rev. 2008 Sep;60(12):1329-46
18562040
Nat Nanotechnol. 2009 Jul;4(7):411-4
19581891
Science. 2004 Mar 19;303(5665):1818-22
15031496
Eur J Pharm Sci. 2007 Nov;32(3):159-68
17707615
Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7
17935286
Anticancer Res. 2007 Jul-Aug;27(4B):2217-25
17695506
Nat Rev Drug Discov. 2004 Jun;3(6):488-99
15173838
Nat Biotechnol. 2005 Sep;23(9):1147-57
16151408
Cancer Biother Radiopharm. 2009 Aug;24(4):453-60
19694580
Clin Cancer Res. 2006 Nov 15;12(22):6800-7
17121901
J Nucl Med. 2008 Aug;49(8):1371-9
18632815
J Nucl Med. 2007 Nov;48(11):1862-70
17942800
Int J Cancer. 2007 May 1;120(9):1951-7
17278104
J Nucl Med. 2009 Apr;50(4):644-52
19289440
Nat Rev Cancer. 2008 Jun;8(6):473-80
18469827
Nucl Med Biol. 2007 May;34(4):415-23
17499731
J Pharmacol Exp Ther. 2004 Feb;308(2):419-25
14610219
J Control Release. 2008 Sep 10;130(2):107-14
18582982
Occup Med (Lond). 2006 Aug;56(5):307-11
16868128
Bioconjug Chem. 2008 Sep;19(9):1921-6
18754572
Acc Chem Res. 2008 Dec;41(12):1630-40
18698851
Bioconjug Chem. 2007 Jan-Feb;18(1):101-8
17226962
J Nucl Med. 1996 Feb;37(2):326-32
8667071
Nano Lett. 2008 Aug;8(8):2517-25
18624389
J Nucl Med. 2007 Jul;48(7):1180-9
17607040
J Nucl Med. 2003 Dec;44(12):1992-9
14660726
Nucl Med Biol. 2010 Jan;37(1):95-104
20122674
J Drug Target. 2008 Aug;16(7):626-37
18686134
Adv Drug Deliv Rev. 1999 Apr 5;37(1-3):53-61
10837726
J Nucl Med. 2007 Nov;48(11):1767-76
17942813
Anticancer Res. 2009 Jun;29(6):2111-20
19528471
J Pharm Sci. 2003 Sep;92(9):1893-904
12950007
Nature. 1996 Apr 11;380(6574):561-2
8606781
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):685-90
19129498
Prog Lipid Res. 2000 Sep;39(5):461-75
11082507
Adv Drug Deliv Rev. 1999 Apr 5;37(1-3):13-32
10837724
J Nucl Med. 2004 Feb;45(2):253-60
14960644
Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205
15717745
J Nucl Med. 2003 Sep;44(9):1469-78
12960194
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):833-41
16965871
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S84-7
19406654
Cancer Res. 2005 May 1;65(9):3643-55
15867359
Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205
16763815
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2235-44
18566815
Mol Pharm. 2006 Sep-Oct;3(5):525-30
17009851
Cancer Biother Radiopharm. 2008 Dec;23(6):749-58
19111045
J Liposome Res. 2007;17(1):1-14
17454399
Bioconjug Chem. 2009 Feb;20(2):397-401
19138113
Bioconjug Chem. 2003 Jan-Feb;14(1):158-67
12526705